Formulary Search Results for: ULIPRISTAL ACETATE
7.2.3 Preparations for uterine fibroids and endometriosis - View Category
Restrictions:
The treatment of moderate to severe symptoms of uterine fibroids in adult women is restricted to the following MHRA advice:
- intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age who are not eligible for surgery or where surgery has failed
- treatment is to be initiated and supervised by a physician experienced in the diagnosis and treatment of uterine fibroids
Please refer to MHRA information prior to initiation.
7.3.5 Emergency contraception - View Category
Prescribing Notes:
- Ulipristal is licensed for use in women presenting up to 120 hours after unprotected intercourse for whom the insertion of an IUD is not acceptable.
- Please follow the FSRH guidance for appropriate use.
11.4.1 Eye-corticosteroids - View Category
9.5.2.2 Phosphate-binding agents - View Category
7.3.2.2 Parenteral progestogen-only contraceptives - View Category
4.8.1 Control of the epilepsies - View Category
Restrictions:
Restricted to initiation by specialists in epilepsy.
Prescribing Notes:
Use as monotherapy in the treatment of partial-onset seizures, with or without generalisation, in adults with newly diagnosed epilepsy is not recommended for use in NHSScotland by the SMC and is non-Formulary.
3.4.3 Allergic emergencies - View Category
Restrictions:
It is restricted to specialist use only on the advice of the Immunology Service.
8.3.2 Progestogens - View Category
8.2.5 Immunomodulating drugs used in Multiple Sclerosis - View Category
Restrictions:
Restricted to specialist use only. Restricted to use under the provision of the ‘Risk Sharing Scheme’ between the Scottish Executive Health Department and the manufacturers (NHS HDL (2002)6).
6.4.1.2 Progestogens - View Category
Prescribing Notes:
The use of medroxyprogesterone tablets for postponing menstruation is off-label, and only for use in patients at higher risk of VTE or where norethisterone is unsuitable. Further guidance is available from the Specialist Pharmacy Service.